Document Detail


Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
MedLine Citation:
PMID:  19618317     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Increased sympathetic activity might be related to pathogenesis of hypertension as well as to end organ damage. Animal studies suggest that statins decrease sympathetic activity and increase baroreceptor reflex sensitivity (BRS). AIM: To examine whether atorvastatin decreases muscle sympathetic nerve activity (MSNA) and BRS in hypercholesterolaemic and hypertensive patients. METHODS: Ten patients with essential hypertension and untreated hypercholesterolaemia (aged 43 +/- 12 years) and eight healthy subjects (aged 37 +/- 7 years) were enrolled in the study. In both groups the recordings of microneurography, ECG, blood pressure and BRS were performed twice, before and after 8 weeks during which the patients (but not controls) were treated with atorvastatin. RESULTS: Compared with controls, the patients had higher MSNA values (36.0 +/- 6.6 vs. 29.8 +/- 3.7 bursts/minute), mean BP levels (145.1 +/- 10 vs. 124.1 +/- 11.1 mmHg) and total cholesterol concentration (252.6 +/- 22.6 vs. 179.8 +/- 20.7 mg/dl) baseline values. Statin therapy resulted in a decrease of total cholesterol (252.6 +/- 22.0 vs. 173.8 +/- 26.2 mg/dl, p < 0.05) and MSNA (36.0 +/- 6.6 vs. 28.6 +/- 4.8 bursts/min, p < 0.05), whereas BRS values were increased (12.6 +/- 5.6 vs. 18.1 +/- 5.9 ms/mmHg, p < 0.05). Post-treatment BRS was inversely related to post-treatment MSNA (r = -0.73, p < 0.05). In the controls there were no changes in MSNA (29.8 +/- 3.7 vs. 28.9 +/- 2.9 bursts/min), BRS (11.9 +/- 5.0 vs. 13.1 +/- 4.8 ms/mmHg), total cholesterol, BP and heart rate between the first and the second measurement. CONCLUSION: Atorvastatin reduces MSNA and increases BRS in hypertensive and hypercholesterolaemic patients. Decrease in sympathetic activity may be the result of improvement of baroreceptor function by atorvastatin.
Authors:
Maciej Siński; Jacek Lewandowski; Agnieszka Ciarka; Joanna Bidiuk; Piotr Abramczyk; Anna Dobosiewicz; Zbigniew Gaciong
Related Documents :
16258027 - Vascular endothelial-derived semaphorin 3 inhibits sympathetic axon growth.
7900887 - Impairment of cardiopulmonary baroreflexes during the newborn period.
12462357 - Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure an...
23535987 - Relationships between metrics of visit-to-visit variability of blood pressure.
10457077 - Contribution of the leg vasculature to hypotensive effects of an antiorthostatic postur...
23449607 - Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augm...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Kardiologia polska     Volume:  67     ISSN:  0022-9032     ISO Abbreviation:  Kardiol Pol     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-07-20     Completed Date:  2009-10-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376352     Medline TA:  Kardiol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  613-20     Citation Subset:  IM    
Affiliation:
Warszawski Uniwersytet Medyczny, Banacha 1a, 02-097 Warszawa, Poland. msinski@am.edu.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anticholesteremic Agents / therapeutic use*
Baroreflex / drug effects*
Heptanoic Acids / therapeutic use*
Humans
Hypercholesterolemia / complications,  drug therapy*
Hypertension / complications*
Male
Pressoreceptors / drug effects
Pyrroles / therapeutic use*
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin
Comments/Corrections
Comment In:
Kardiol Pol. 2009 Jun;67(6):621-2   [PMID:  19852090 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interleukin-1b and interleukin-1 receptor inhibitor gene cluster polymorphisms in patients with coro...
Next Document:  Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 m...